BiotechTube
Artivion

Artivion

AORT
United States

Artivion is a global medical device company dedicated to advancing the treatment of aortic diseases through a focused portfolio of surgical and endovascular solutions. The company's strategic acquisitions, including Ascyrus Medical and the On-X heart valve technology, have positioned it as a leader in aortic arch repair and mechanical heart valves. With over 1,600 employees worldwide, Artivion is driving patient-powered progress by collaborating with surgeons to address their most difficult challenges, supported by a robust clinical pipeline and recent regulatory milestones like the FDA HDE for its AMDS device.

artivion.com

AORT · Stock Price

USD 36.12+11.62 (+47.43%)
Market Cap: $1.7B

Historical price data

AI Company Overview

Artivion is a global medical device company dedicated to advancing the treatment of aortic diseases through a focused portfolio of surgical and endovascular solutions. The company's strategic acquisitions, including Ascyrus Medical and the On-X heart valve technology, have positioned it as a leader in aortic arch repair and mechanical heart valves. With over 1,600 employees worldwide, Artivion is driving patient-powered progress by collaborating with surgeons to address their most difficult challenges, supported by a robust clinical pipeline and recent regulatory milestones like the FDA HDE for its AMDS device.

Cardiovascular DiseaseAortic DiseaseStructural Heart Disease

Technology Platform

Artivion's core expertise integrates cryopreserved tissue processing, mechanical heart valve engineering, hybrid aortic arch device design, and endovascular stent graft systems to provide a comprehensive portfolio for the surgical and endovascular treatment of aortic diseases.

Pipeline

1
1 drug in pipeline1 in Phase 3
DrugIndicationStageWatch
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinAortic Valve DiseasePhase 3

Funding History

2
Total raised:$100M
Debt$100M
IPOUndisclosed

Opportunities

The primary growth opportunity is the potential full PMA approval and broad commercialization of the AMDS Hybrid Prosthesis for acute Type A aortic dissections, a large unmet need.
Additional opportunities include international expansion of its portfolio, cross-selling its comprehensive aortic solutions to surgical centers, and generating long-term clinical data to support the value of its On-X valves with low anticoagulation therapy.

Risk Factors

Key risks include regulatory delays or rejection of the AMDS PMA application, intense competition from larger medical device companies, pricing pressure and reimbursement challenges for novel technologies, and execution risks in integrating acquisitions and managing a global supply chain for tissue-based products.

Competitive Landscape

Artivion competes with large medtech firms like Medtronic, Gore, and Abbott in aortic stent grafts and heart valves. Its differentiation lies in its specialized, aortic-focused portfolio that offers a unique combination of hybrid arch technology (AMDS), leading mechanical valves (On-X), and cryopreserved allografts, providing a comprehensive solution set for aortic surgeons.

More companies in Regenerative Medicine →More companies in United States →